title: Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study.
abstract: OBJECTIVE
  Fibrotic severity, biochemical indices of poor liver function, and sporadic transmission are independent predictors of liver complications among people with chronic hepatitis C. After accounting for these factors, we tested whether interferon treatment or the treatment response reduces the rate of liver cancer, liver-related death or transplantation, and other liver complications during extended follow-up.
  
  
  METHODS
  Liver clinic cohort of 455 patients with histologically proven chronic hepatitis C was followed prospectively for median 9 yr (IQ 6, 11 yr); 384 received interferon, 343 completed a treatment course. Liver complications were assessed in relation to treatment and treatment response in univariate and multivariate models, and survival to onset of liver-related complications was determined.
  
  
  RESULTS
  The annual incidence of total liver complications was 1.5% in treated and 2.9% in untreated patients and appeared quasilinear throughout 9-yr follow-up. Interferon treatment did not influence the rate of liver complications. However, the rate of complications increased exponentially with transition of the treatment response from sustained viral response (SVR), through response-relapse to nonresponse (or no treatment). By univariate analysis, response to interferon treatment was a significant predictor of complications. After adjustment for fibrosis score, serum albumin concentration and mode of transmission in a multivariate model, treatment response just failed to reach significance (p= 0.058) as a predictor of outcome.
  
  
  CONCLUSIONS
  Response to antiviral therapy, and particularly SVR, appears to reduce liver complications in chronic hepatitis C. However, in the absence of an antiviral treatment response, a course of interferon does not reduce risks of liver cancer or liver failure.
authors.affiliation: Storr Liver Unit, Westmead Millennium Institute and University of Sydney at Westmead Hospital, Westmead, NSW 2145, Australia.
authors.forename: Shirley A
authors.initials: SA
authors.lastname: Coverdale
authors.forename: Mahbub H
authors.initials: MH
authors.lastname: Khan
authors.forename: Karen
authors.initials: K
authors.lastname: Byth
authors.forename: Rita
authors.initials: R
authors.lastname: Lin
authors.forename: Martin
authors.initials: M
authors.lastname: Weltman
authors.forename: Jacob
authors.initials: J
authors.lastname: George
authors.forename: Dev
authors.initials: D
authors.lastname: Samarasinghe
authors.forename: Christopher
authors.initials: C
authors.lastname: Liddle
authors.forename: James G
authors.initials: JG
authors.lastname: Kench
authors.forename: Evelyn
authors.initials: E
authors.lastname: Crewe
authors.forename: Geoffrey C
authors.initials: GC
authors.lastname: Farrell
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008107:Liver Diseases / Q000188:drug therapy / Q000209:etiology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha